<DOC>
	<DOCNO>NCT00031863</DOCNO>
	<brief_summary>RATIONALE : Rofecoxib may stop growth cancer stop blood flow tumor kill tumor cell remain surgery . It yet know rofecoxib effective treating colorectal cancer . PURPOSE : Randomized phase III trial determine effectiveness give rofecoxib surgery treat patient stage II stage III colorectal cancer .</brief_summary>
	<brief_title>Rofecoxib After Surgery Treating Patients With Stage II Stage III Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient previously resect stage II III colorectal cancer treat rofecoxib v placebo administer least 2 year vs 5 year . - Compare relapse-free survival patient treat regimen . OUTLINE : This randomize , placebo-controlled , double-blind , multicenter study . Patients stratify accord participate center , site disease ( colon v rectum ) , disease stage ( II v III ) , age , adjuvant chemotherapy ( yes v ) , type chemotherapy regimen ( 1 vs 2 v 3 v 4 v 5 ) . Within 3 month surgical resection alone completion adjuvant radiotherapy and/or chemotherapy surgical resection , patient randomize one four treatment arm . - Arm I : Patients receive oral rofecoxib daily 2 year . - Arm II : Patients receive oral rofecoxib daily 5 year . - Arm III : Patients receive oral placebo daily 2 year . - Arm IV : Patients receive oral placebo daily 5 year . Treatment continue arm absence disease recurrence unacceptable toxicity . PROJECTED ACCRUAL : A total 7,000 patient ( 1,750 per treatment arm ) accrue study within 5 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rofecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal carcinoma Stage II ( T34 , N0 , M0 ) stage III ( T , N12 , M0 ) disease Completely resect primary tumor without gross microscopic evidence residual disease Must receive potentially curative therapy within past 12 week , include follow : Surgery alone Surgery plus radiotherapy and/or chemotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST/ALT great 1.5 time ULN Renal : Creatinine clearance great 30 mL/min Cardiovascular : No severe congestive heart failure Other : Not pregnant nursing Fertile patient must use effective contraception No active peptic ulcer gastrointestinal bleeding within past year No inflammatory bowel disease No known sensitivity rofecoxib No prior adverse reaction nonsteroidal antiinflammatory drug ( NSAIDs ) ( e.g. , asthma , acute rhinitis , nasal polyp , angioneurotic edema , urticaria ) No malignancy within past 10 year except adequately treat carcinoma situ cervix basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics Other : No concurrent longterm NSAIDs except lowdose aspirin ( 80 mg/day ) cardioprophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
</DOC>